Climb Bio (CLYM) Consolidated Net Income (2020 - 2026)

Climb Bio has reported Consolidated Net Income for 7 years, with the latest figure at -$13.7 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 33.93% year-over-year to -$13.7 million; the trailing twelve-month figure through Mar 2026 stood at -$52.5 million (up 43.49% YoY), and the FY2025 full-year result was -$59.6 million, up 19.39% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$13.7 million, up from -$17.5 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$1.7 million in Q1 2024, with the low at -$54.9 million in Q2 2024.
• Historically, Consolidated Net Income has averaged -$13.3 million across 5 years, with a median of -$8.9 million in 2024.
• Annual changes were most pronounced in 2024 — Consolidated Net Income soared 92.62% — and 2025, when it sank 1145.85%.
• Climb Bio's Consolidated Net Income stood at -$8.8 million in 2022, then soared by 57.1% to -$3.8 million in 2023, then plunged by 122.37% to -$8.4 million in 2024, then slumped by 108.22% to -$17.5 million in 2025, then advanced by 21.6% to -$13.7 million in 2026.
• The last three Consolidated Net Income figures came in at -$13.7 million (Q1 2026), -$17.5 million (Q4 2025), and -$12.9 million (Q3 2025), per Business Quant data.